Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection

International Reviews of Immunology

Volumn 33, Issue 1, 2014, Pages 45-53

  Chen, Rong Fu ^a   Lee, Chun Yi ^b  

^a Show Chwan Health Care System   (Taiwan)

^b CHANG BING SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adenovirus; CAR; CD46; Innate immunity; Interferon vector

Indexed keywords

ADENOVIRUS VECTOR; CELL RECEPTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYTOKINE; DESMOGLEIN 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MEMBRANE COFACTOR PROTEIN; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ADENOVIRUS 11; ADENOVIRUS 12; ADENOVIRUS 14; ADENOVIRUS 26; ADENOVIRUS 35; ADENOVIRUS 48; ADENOVIRUS 7; ADENOVIRUS INFECTION; CYTOKINE RESPONSE; DISEASE SEVERITY; HUMAN; HUMAN ADENOVIRUS 2; HUMAN ADENOVIRUS 5; INNATE IMMUNITY; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; CYTOKINES; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; RECEPTORS, VIRUS; VIRAL LOAD;

EID: 84893086283     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2013.823420     Document Type: Review

References (54)

1. Tabain I, Ljubin-Sternak S, Cepin-Bogovic J, et al. Adenovirus respiratory infections in hospitalized children: Clinical findings in relation to species and serotypes. Pediatr InfectDis J 2012;31(7):680-684
2. Thaci B, Ulasov IV, Wainwright DA, Lesniak MS. The challenge for gene therapy: Innate immune response to adenoviruses. Oncotarget 2011;2(3):113-121
3. Sdiri-Loulizi K, Gharbi-Khelifi H, de Rougemont A, et al. Molecular epidemiology of human astrovirus and adenovirus serotypes 40/41 strains related to acute diarrhea in Tunisian children. J Med Virol 2009;81(11):1895-1902
4. Moro MR, Bonville CA, Suryadevara M, et al. Clinical features, adenovirus types, and local production of inflammatorymediators in adenovirus infections. Pediatr Infect Dis J 2009;28(5):376-380
5. Greber UF, Arnberg N, Wadell G, et al. Adenoviruses - from pathogens to therapeutics: A report on the 10th International AdenovirusMeeting. CellMicrobiol 2013;15(1):16-23
6. Harrison SC. Virology. Looking inside adenovirus. Science 2010;329(5995):1026-1027
7. Ferreon JC, Martinez-Yamout MA, Dyson HJ, Wright PE. Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein. Proc Natl Acad Sci USA 2009 Aug 11;106(32):13260-13265
8. Soria C, Estermann FE, Espantman KC, O'Shea CC. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 2010;466(7310):1076-1081
9. Fechner H,Haack A,WangH, et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999;6(9):1520-1535
10. Sirena D, Lilienfeld B, Eisenhut M, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004;78(9):4454-4462
11. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003;9(11):1408-1412
12. Segerman A, Atkinson JP, Marttila M, et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003;77(17):9183-9191
13. Wu E, Trauger SA, Pache L, et al. Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. J Virol 2004;78(8):3897-3905
14. Riley-Vargas RC, Gill DB, Kemper C, et al. CD46: Expanding beyond complement regulation. Trends Immunol 2004;25(9):496-503
15. WolfrumN, Greber UF. Adenovirus signalling in entry. CellMicrobiol 2013;15(1):53-62
16. Gustafsson DJ, Andersson EK, Hu YL, et al. Adenovirus 11p downregulates CD46 early in infection. Virology 2010;405(2):474-482
17. Wang H, Li ZY, Liu Y, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011;17(1):96-104
18. Trinh HV, Lesage G, Chennamparampil V, et al. Avidity binding of human adenovirus serotypes 3and 7 to the membrane cofactor CD46 triggers infection. J Virol. 2012;86(3):1623-1637
19. Cashman SM, Morris DJ, Kumar-Singh R. Adenovirus type 5 pseudotyped with adenovirus type 37fiber uses sialic acid as a cellular receptor. Virology 2004;324(1):129-139
20. Nilsson EC, StormRJ, Bauer J, et al.The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis. NatMed 2011;17(1):105-109
21. Dalrymple N,Mackow ER. Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors. J Virol 2011;85(18):9478-9485
22. Hallak LK, SpillmannD,Collins PL, PeeplesME. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 2000;74(22):10508-10513
23. Hilgard P, Stockert R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 2000;32(5):1069-1077
24. Tuve S, Wang H, Jacobs JD, et al. Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog 2008;4(10):e1000189
25. Gout E, Schoehn G, Fenel D, et al.The adenovirus type 3 dodecahedron's RGD loop comprises an HSPG binding site that influences integrin binding. J Biomed Biotechnol 2010;2010:541939
26. Kalin S, Amstutz B, Gastaldelli M, et al. Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35. J Virol 2010;84(10):5336-5350
27. Wu E, Nemerow GR. Virus yoga: The role of flexibility in virus host cell recognition. TrendsMicrobiol 2004;12(4):162-169
28. Meier O, Greber UF. Adenovirus endocytosis. J GeneMed 2003;5(6):451-462
29. Zhang Y, Bergelson JM. Adenovirus receptors. J Virol 2005;79(19):12125- 12131
30. Heim A. Advances in the management of disseminated adenovirus disease in stem cell transplant recipients: Impact of adenovirus load (DNAemia) testing. Expert Rev Anti Infect Ther 2011;9(11): 943-945
31. Claas EC, SchilhamMW,deBrouwerCS, et al. Internally controlled real-time PCRmonitoring of adenovirusDNAload in serumor plasma of transplant recipients. JClinMicrobiol 2005;43(4):1738-1744
32. Ganzenmueller T, Buchholz S, Harste G, et al. High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load. J Clin Virol 2011;52(1): 55-59
33. Erard V, Huang ML, Ferrenberg J, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: Viral load as amarker for invasive disease. Clin Infect Dis 2007;45(8):958-965
34. Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol 2012;86(18):9590-9598
35. Zsengeller Z, Otake K, Hossain SA, et al. Internalization of adenovirus by alveolarmacrophages initiates early proinflammatory signaling during acute respiratory tract infection. J Virol 2000;74(20): 9655-9667
36. Diaz PV, Calhoun WJ, Hinton KL, et al. Differential effects of respiratory syncytial virus and adenovirus on mononuclear cell cytokine responses. Am J Respir Crit CareMed 1999;160(4):1157-1164
37. Nazir SA,Metcalf JP. Innate immune response to adenovirus. J InvestigMed 2005;53(6):292-304
38. Zhang P, SummerWR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000;173:39-51
39. Pitkaranta A,Hovi T. Induction of interferon in human leukocyte cultures by natural pathogenic respiratory viruses. J Interferon Res 1993;13(6):423-426
40. Weber F, Wagner V, Kessler N, Haller O. Induction of interferon synthesis by the PKR-inhibitory VA RNAs of adenoviruses. J Interferon Cytokine Res 2006;26(1):1-7
41. Schaack J. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral Immunol 2005;18(1):79-88
42. Pahl JH, Verhoeven DH, Kwappenberg KM, et al. Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling.Mol Immunol 2012;51(1):91-100
43. Leopold PL, Wendland RL, Vincent T, Crystal RG. Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J Virol 2006;80(20): 10237-10247
44. Timpe JM, Verrill KC, Trempe JP. Effects of adeno-associated virus on adenovirus replication and gene expression during coinfection. J Virol 2006;80(16):7807-7815
45. Tullis GE, Shenk T. Efficient replication of adeno-associated virus type 2 vectors: A cis-acting element outside of the terminal repeats and aminimal size. J Virol 2000;74(24):11511-11521
46. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101(8):2963-2972
47. Bartlett JS, Samulski RJ, McCown TJ. Selective and rapid uptake of adeno-associated virus type 2 in brain. HumGeneTher 1998;9(8):1181-1186
48. Richter M, Iwata A, Nyhuis J, et al. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomics 2000;2(3):117-127
49. Koeberl DD, Alexander IE, Halbert CL, et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 1997;94(4):1426-1431
50. Surosky RT, UrabeM, Godwin SG, et al. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997;71(10):7951-7959
51. Zaiss AK, Liu Q, Bowen GP, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002;76(9):4580-4590
52. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999;6(9):1574-1583
53. Sun JY, Anand-Jawa V, Chatterjee S,Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003;10(11):964-976
54. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. GeneTher 2003;10(11):955-963